Aurisco Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	792.37	769.44	545.84	391.74	444.61
Trading Asset Securities	161.52	299.83	-	-	-
Cash & Short-Term Investments	953.9	1,069	545.84	391.74	444.61
Cash Growth	-10.79%	95.89%	39.34%	-11.89%	-21.18%
Accounts Receivable	434.32	350.87	290.78	222.11	140.72
Other Receivables	4.02	4.23	8.31	3.9	6.19
Receivables	438.34	355.11	299.09	226.01	146.91
Inventory	644.88	589.72	509.8	444.94	326.8
Prepaid Expenses	-	-	-	0.17	-
Other Current Assets	19.48	32.7	11.31	25.5	21.48
Total Current Assets	2,057	2,047	1,366	1,088	939.8
Property, Plant & Equipment	1,779	1,497	878.33	674.18	593.26
Long-Term Investments	166.36	133.47	79.3	55.3	15.3
Other Intangible Assets	160.37	161.46	121.4	122.71	40.42
Long-Term Deferred Tax Assets	22.54	15.78	14.29	15.24	8.56
Long-Term Deferred Charges	4.72	5.32	6.91	11.37	-
Other Long-Term Assets	32.03	17.41	108.35	68.14	124.09
Total Assets	4,222	3,877	2,575	2,035	1,721
Accounts Payable	338.85	297.39	242.53	102.43	128.2
Accrued Expenses	106.81	121.64	92.89	51.95	40.89
Short-Term Debt	20.02	20.02	40.04	30	-
Current Portion of Long-Term Debt	-	-	-	1.3	-
Current Portion of Leases	-	5.64	5.14	4.93	4.06
Current Income Taxes Payable	-	25	16.64	12.85	8.61
Current Unearned Revenue	3.06	6.6	22.25	0.98	8.96
Other Current Liabilities	52.33	55.74	81.53	117.75	2.36
Total Current Liabilities	521.06	532.04	501.02	322.17	193.08
Long-Term Debt	917.96	907.09	60.46	4.22	-
Long-Term Leases	15.12	15.1	11.24	12.23	13.91
Long-Term Unearned Revenue	105.91	91.57	34.02	7.69	4.53
Long-Term Deferred Tax Liabilities	4.38	0.1	0.28	4.81	1.92
Total Liabilities	1,564	1,546	607.03	351.13	213.44
Common Stock	406.2	406.2	406.2	406.2	401
Additional Paid-In Capital	613.96	606.5	584.93	553.36	491.73
Retained Earnings	1,573	1,241	975.92	751.49	592.71
Treasury Stock	-55.26	-22.86	-45.72	-57.15	-
Comprehensive Income & Other	119.51	100.34	46.25	22.28	20.8
Total Common Equity	2,658	2,332	1,968	1,676	1,506
Minority Interest	-	-	-	7.99	1.75
Shareholders' Equity	2,658	2,332	1,968	1,684	1,508
Total Liabilities & Equity	4,222	3,877	2,575	2,035	1,721
Total Debt	953.1	947.85	116.88	52.69	17.97
Net Cash (Debt)	0.8	121.42	428.95	339.05	426.64
Net Cash Growth	-99.34%	-71.69%	26.52%	-20.53%	-24.37%
Net Cash Per Share	0.00	0.30	1.05	0.84	1.06
Filing Date Shares Outstanding	385.22	406.2	406.2	406.2	401
Total Common Shares Outstanding	385.22	406.2	406.2	406.2	401
Working Capital	1,536	1,515	865.02	766.19	746.72
Book Value Per Share	6.90	5.74	4.84	4.13	3.76
Tangible Book Value	2,497	2,170	1,846	1,553	1,466
Tangible Book Value Per Share	6.48	5.34	4.55	3.82	3.66
Buildings	-	291.81	291.85	289.74	283.37
Machinery	-	735.79	640.39	587.27	485.03
Construction In Progress	-	869.74	280.64	79.93	47.83

Source: S&P Global Market Intelligence. Standard template. Financial Sources.